TreeFrog Therapeutics secures €30 million from EIB TreeFrog Therapeutics, a French biotech specializing in cell therapy, has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson’s Disease to the clinic. This cell therapy has…..
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing of its stem cell-based therapy First clinical batches of ProtheraCytes® are planned for 2026 CellProthera, a French regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for its…..
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies CRISPR Therapeutics, a Swiss biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a sino-american clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, have concluded a…..
Launch of UMBRELLA study to personnalise post-treatment follow-up for cancer patients On May 19, 2025, Gustave Roussy announced the launch of UMBRELLA, a ground-breaking phase III clinical trial that could profoundly transform how cancer patients are monitored after curative treatment. The objective is to personalise post-treatment follow-up based on the…..
8.3 million euros for doctoral programme in regenerative medicine and ATMP Marie Jönsson, grant manager Stem Cell Center and Mattias Magnusson, director of RAMP-UP at the Lund Research School in Stem Cell Biology and group leader at the Stem Cell Center. ©Alexis Bento Luis Lund University in Sweden has been…..
National Initiative for RNA Biology and its Applications launched in Singapore RNA biology and its applications has been identified as a rapidly expanding field of critical importance to Singapore’s future health and economic needs. Singapore Deputy Prime Minister Mr Heng Swee Keat officiated at the inauguration of the National Initiative…..
Merck KGaA to triple its ADC manufacturing capacity in St. Louis The German science and technology group Merck KGaA has announced a € 70 million expansion of its antibody-drug conjugates (ADC) manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment…..
Vivet Therapeutics receives €4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis Funding from French Government as part of the France Health Innovation Plan 2030 Vivet Therapeutics, a French clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders,…..
AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement ©DZIF AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to identify novel targets for antiviral therapy and to discover new active agents for…..
Using artificial intelligence to discover therapeutic antibodies Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics. The EMBL scientists who developed the AI-driven technology to design proteins that DenovAI will harness. From left to right:…..
- 1
- 2
- 3
...
- 22
- Page Suivante
